Invesco Ltd. Has $2.29 Million Stock Holdings in OPKO Health, Inc. (NASDAQ:OPK)

Invesco Ltd. lowered its stake in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 74.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,554,489 shares of the biotechnology company's stock after selling 4,475,485 shares during the quarter. Invesco Ltd. owned about 0.23% of OPKO Health worth $2,285,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of OPK. Wells Fargo & Company MN lifted its position in shares of OPKO Health by 14.9% in the 4th quarter. Wells Fargo & Company MN now owns 229,262 shares of the biotechnology company's stock worth $337,000 after acquiring an additional 29,738 shares during the period. ExodusPoint Capital Management LP acquired a new position in shares of OPKO Health in the fourth quarter valued at $255,000. Norges Bank bought a new position in OPKO Health in the fourth quarter worth $1,657,000. KLP Kapitalforvaltning AS acquired a new stake in OPKO Health during the fourth quarter worth $109,000. Finally, Tejara Capital Ltd increased its holdings in OPKO Health by 11.3% in the 4th quarter. Tejara Capital Ltd now owns 1,225,650 shares of the biotechnology company's stock valued at $1,802,000 after buying an additional 124,524 shares during the period. 64.63% of the stock is currently owned by institutional investors and hedge funds.

OPKO Health Price Performance

Shares of NASDAQ:OPK traded down $0.03 during trading on Thursday, reaching $1.35. The stock had a trading volume of 4,469,871 shares, compared to its average volume of 3,890,683. The stock has a market capitalization of $906.59 million, a PE ratio of -7.11 and a beta of 1.78. OPKO Health, Inc. has a 52 week low of $1.15 and a 52 week high of $2.04. The business's 50-day moving average price is $1.63 and its 200 day moving average price is $1.57. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69.

OPKO Health (NASDAQ:OPK - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.03). The company had revenue of $149.90 million for the quarter, compared to analyst estimates of $163.13 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The firm's quarterly revenue was down 13.7% on a year-over-year basis. During the same quarter last year, the company earned ($0.12) EPS. As a group, equities analysts predict that OPKO Health, Inc. will post -0.25 earnings per share for the current year.

Insider Activity

In other news, CEO Phillip Md Et Al Frost purchased 200,000 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The shares were acquired at an average price of $1.74 per share, for a total transaction of $348,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 213,501,448 shares in the company, valued at approximately $371,492,519.52. The trade was a 0.09 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have purchased 767,434 shares of company stock valued at $1,238,312 over the last three months. 49.69% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on OPK shares. Barrington Research reiterated an "outperform" rating and set a $2.25 target price on shares of OPKO Health in a research report on Thursday. StockNews.com raised OPKO Health from a "sell" rating to a "hold" rating in a report on Monday, March 3rd. JPMorgan Chase & Co. initiated coverage on OPKO Health in a research note on Friday, April 25th. They issued a "neutral" rating on the stock. Finally, HC Wainwright restated a "buy" rating and set a $3.00 target price on shares of OPKO Health in a research report on Monday, April 7th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $2.75.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.